Search

Your search keyword '"Jenner M"' showing total 388 results
Start Over Author "Jenner M"
388 results on '"Jenner M"'

1. Global conservation genomics of blue whales calls into question subspecies taxonomy and refines knowledge of population structure.

Author

Attard, C. R. M., Sandoval‐Castillo, J., Lang, A. R., Vernazzani, B. G., Torres, L. G., Baldwin, R., Jenner, K. C. S., Gill, P. C., Burton, C. L. K., Barceló, A., Sironi, M., Jenner, M.‐N. M., Morrice, M. G., Beheregaray, L. B., and Möller, L. M.

Subjects
BLUE whale, NATURAL selection, BALEEN whales, GENETIC variation, SPECIES diversity
Abstract

Blue whales (Balaenoptera musculus) are the largest living animal and, like other baleen whales, became endangered due to whaling. Here, we used population genomics to infer the number, distribution and other characteristics of subspecies and populations. We used the largest DNA dataset in blue whales, both in terms of genomic markers (16,661 SNPs and mtDNA) and geographic coverage (n = 276 for SNPs; n = 531 for mtDNA). We found greatest divergence among the eastern Pacific, Indo‐western Pacific and Antarctic blue whales. There were indications that natural selection in different environments promoted divergence among these groupings. Within these regions, there was divergence between the eastern North and eastern South Pacific, and among the eastern Indian Ocean, the western South Pacific and the northern Indian Ocean. There was no divergence within the Antarctic. These findings are consistent with the current classification of Antarctic and Indo‐western Pacific blue whales in the Southern Hemisphere as different subspecies but call into question the subspecies taxonomy of eastern Pacific blue whales. The study shows that opposite breeding seasons on either side of the equator do not necessarily inhibit connectivity across the equator, and reinforces that population structure needs to be well understood to conserve the diversity within species. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Total Root Electron Content: A New Metric for the Ionosphere Below Low Earth Orbiting Satellites.

Author

Jenner, M., Coïsson, P., Hulot, G., Buresova, D., Truhlik, V., and Chauvet, L.

Subjects
*ELECTRON distribution, *IONOSPHERIC electron density, *LOW earth orbit satellites, *ELECTRON density, *ATMOSPHERE
Abstract

Powerful lightning strikes generate broadband electromagnetic signals. At Extremely Low Frequencies (ELF), the signal partly leaks into the ionosphere and produces whistlers that can be detected by satellites. Indeed, the satellites of the European Space Agency (ESA) Swarm Earth Explorer mission can detect those signals during 250 Hz burst‐mode acquisition campaigns of their Absolute Scalar Magnetometers (ASM). The dispersion of these whistlers depends on their propagation path and the distribution of ionization in the ionosphere crossed along that path. In this paper, we introduce a technique to derive a new measure of ionosphere electron content, the Total square‐Root Electron Content (TREC), using the arrival times of two frequencies of the whistler signal. We validate this approach by using data from ionosondes and from in situ measurements of the electron density at Swarm location. This technique brings new opportunities for sounding the ionosphere in regions poorly observed by other techniques. Plain Language Summary: A lightning strike generates an electromagnetic impulse that propagates within Earth's atmosphere and eventually leaks out into the ionosphere. As it propagates through the ionosphere toward low‐Earth orbiting (LEO) satellites, it gets converted into a so‐called whistler, with high frequencies arriving earlier than low frequencies. This frequency dispersion depends on the state of the ionosphere. Here, we analyse such whistler waves detected by magnetometers onboard the European Space Agency Swarm satellites to recover information about the state of the ionosphere below the satellites. We first introduce a new metric, the Total Root Electron Content (TREC), which quantifies the cumulative value of the square root of electron density along the path of the whistler. We next propose a method to recover the TREC from the analysis of the whistler dispersion. We finally validate this method by using independently derived ionospheric electron density profiles to infer expected TREC values. Our results show that whistlers detected by LEO satellites can be used to locally improve the widely used empirical International Reference Ionosphere model. Such whistler inferred TREC values could be used to sound the ionosphere above places difficult to sample with conventional measuring techniques, and help better model and understand the highly dynamic ionosphere. Key Points: Total square‐Root Electron Content (TREC) is a new measure of the ionospheric electron content for electromagnetic signals in the ELF bandA method to retrieve TREC from fractional‐hop whistlers in the ELF detected by the ESA Swarm mission is proposedThe method is validated using TREC computed with independently constrained electron density profiles close to the Swarm whistler locations [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. P954: ESTABLISHING THE NATIONAL INSTITUTE FOR HEALTH RESEARCH (NIHR) HEALTH INFORMATICS COLLABORATIVE (HIC) MULTIPLE MYELOMA (MM) REGISTRY

Author

Tayabali, S., primary, Moore, S., additional, Jenner, M., additional, Djebbari, F., additional, Romao, L., additional, English, L., additional, Rodriguez, R., additional, Briot Ribeyre, B., additional, Roadknight, G., additional, Varnai, K., additional, Little, S., additional, Davies, J., additional, Woods, K., additional, Davis, C., additional, Borca, F., additional, Olza Meneses, J., additional, Phan, H., additional, Wong, W. K., additional, and Popat, R., additional

Published
2022
Full Text
View/download PDF

7. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Author

Hájek, R, Masszi, T, Petrucci, M T, Palumbo, A, Rosiñol, L, Nagler, A, Yong, K L, Oriol, A, Minarik, J, Pour, L, Dimopoulos, M A, Maisnar, V, Rossi, D, Kasparu, H, Van Droogenbroeck, J, Yehuda, D B, Hardan, I, Jenner, M, Calbecka, M, Dávid, M, de la Rubia, J, Drach, J, Gasztonyi, Z, Górnik, S, Leleu, X, Munder, M, Offidani, M, Zojer, N, Rajangam, K, Chang, Y-L, San-Miguel, J F, and Ludwig, H

Published
2017
Full Text
View/download PDF

9. Playskin Lift: development and initial testing of an exoskeletal garment to assist upper extremity mobility and function

Author

Lobo, Michele A., Koshy, John, Hall, Martha L., Erol, Ozan, Cao, Huantian, Buckley, Jenner M., Galloway, James C., and Higginson, Jill

Subjects
Child development -- Research, Activities of daily living -- Research, Infants (Premature) -- Research -- Health aspects, Health
Abstract

Background. A person's ability to move his or her arms against gravity is important for independent performance of critical activities of daily living and for exploration that facilitates early cognitive, language, social, and perceptual-motor development. Children with a variety of diagnoses have difficulty moving their arms against gravity. Objective. The purpose of this technical report is to detail the design process and initial testing of a novel exoskeletal garment, the Playskin Lift, that assists and encourages children to lift their arms against gravity. Design. This report details the design theory and process, the device, and the results of field testing with a toddler with impaired upper extremity function due to arthrogryposis multiplex congenita. Results. The Playskin Lift is an inexpensive ( Limitations. This report details initial testing with one child. Future testing with more participants is recommended. Conclusions. These results suggest that by considering the broad needs of users, including cost, accessibility, comfort, aesthetics, and function, we can design inexpensive devices that families and clinicians can potentially fabricate in their own communities to improve function, participation, exploration, and learning for children with disabilities., A person's ability to move his or her arms against gravity is important for independent performance of countless activities of daily living, such as feeding, dressing, and academics. (1,2) Additionally, [...]

Published
2016
Full Text
View/download PDF

16. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Author

Dimopoulos, M. Weisel, K. Moreau, P. Anderson, L.D., Jr. White, D. San-Miguel, J. Sonneveld, P. Engelhardt, M. Jenner, M. Corso, A. Dürig, J. Pavic, M. Salomo, M. Casal, E. Srinivasan, S. Yu, X. Nguyen, T.V. Biyukov, T. Peluso, T. Richardson, P.

Subjects
hemic and lymphatic diseases
Abstract

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%; P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments. © 2020, The Author(s).

Published
2021

17. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Author

Dimopoulos, M. Bringhen, S. Anttila, P. Capra, M. Cavo, M. Cole, C. Gasparetto, C. Hungria, V. Jenner, M. Vorobyev, V. Ruiz, E.Y. Yin, J.Y. Saleem, R. Hellet, M. Macé, S. Paiva, B. Vij, R.

Abstract

This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) or had received ≥3 prior lines of therapy incorporating an IMiD and PI. Patients received isatuximab either as monotherapy (20 mg/kg on days 1, 8, 15, and 22 [once weekly] of cycle 1 followed by 20 mg/kg on days 1 and 15 of subsequent cycles; Isa group) or in combination with dexamethasone (40 mg/d [20 mg/d in patients aged ≥75 years] once weekly; Isa-dex group). Treated patients (N = 164) had received a median of 4 (range, 2-10) prior treatment lines. Patients received a median of 5 (1-24) and 7 (1-22) treatment cycles; at data cutoff, 13 (11.9%) of 109 and 15 (27.3%) of 55 patients remained on treatment in the Isa and Isa-dex arms, respectively. Overall response rate (primary efficacy end point) was 23.9% in the Isa arm and 43.6% in the Isa-dex arm (odds ratio, 0.405; 95% confidence interval, 0.192-0.859; P = .008). Median progression-free survival and overall survival were 4.9 and 18.9 months for Isa, and 10.2 and 17.3 months for Isa-dex. Infusion reactions (mostly grade 1/2) and hematologic abnormalities were the most common adverse events. There was a similar incidence of grade 3 or higher infections in both groups (22.0% and 21.8%). In conclusion, addition of dexamethasone to isatuximab increased response rates and survival outcomes with no detrimental effect on safety. This trial was registered at www.clinicaltrials.gov as #NCT01084252. Key Points: • In myeloma patients with a median 4 prior therapy lines, adding dexamethasone to isatuximab increased response rates from 23.9% to 43.6%. • Dexamethasone improved isatuximab efficacy with no detrimental effect on safety, supporting the use of this combination regimen. © 2021 American Society of Hematology

Published
2021

18. Observations of parturition in humpback whales ( Megaptera novaeangliae ) and occurrence of escorting and competitive behavior around birthing females

Author

Ransome, N., Bejder, L., Jenner, M., Penfold, G., Brosig, V.J., Kitson, C., Skjothaug, R., Neilson, E., Loneragan, N.R., Smith, J.N., Ransome, N., Bejder, L., Jenner, M., Penfold, G., Brosig, V.J., Kitson, C., Skjothaug, R., Neilson, E., Loneragan, N.R., and Smith, J.N.

Abstract

Documented cases of cetacean births in the wild are rare. While there are currently no direct observations of a complete humpback whale birth, they are one of the few large whale species where observers have been present during a birthing event. We compiled eye-witnessed accounts of all known humpback whale birthing events and found nine well-documented cases globally (three published and six “new” unpublished). In two-thirds of the accounts another “escort” whale was present and in close association with the birthing female, and of these, most cases involved multiple escorts (n = 4). We describe details of birthing events, including mother, neonate and escort(s)’ behavior, neonate appearance, and discuss reasons for escort presence during parturition. We note that immediately postpartum: (1) blood and/or placenta were not always apparent during above water observations, (2) females often (but not always) supported calves at the surface, (3) constant travel and tail slapping were typical neonate behaviors, (4) two cases of temporary calf abandonment (<10 min), and (5) evidence of shark scavenging (of placenta) and possible predation attempts (of neonate). Lastly, we suggest curled tail flukes as an additional trait for identifying neonates and note that fetal folds are not always evident in newborn humpback whales.

Published
2021

19. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Author

Dimopoulos, M, Weisel, K, Moreau, P, Anderson, LD, White, D, San-Miguel, J, Sonneveld, P, Engelhardt, M, Jenner, M, Corso, A, Duerig, J, Pavic, M, Salomo, M, Casal, E, Srinivasan, S, Yu, X, Nguyen, TV, Biyukov, T, Peluso, T, Richardson, P, Dimopoulos, M, Weisel, K, Moreau, P, Anderson, LD, White, D, San-Miguel, J, Sonneveld, P, Engelhardt, M, Jenner, M, Corso, A, Duerig, J, Pavic, M, Salomo, M, Casal, E, Srinivasan, S, Yu, X, Nguyen, TV, Biyukov, T, Peluso, T, and Richardson, P

Abstract

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%; P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments.

Published
2021

20. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletios, OPTIMISMM trial investigators, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A., Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesu, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thoma, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletio, OPTIMISMM trial investigator, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A., and Hematology

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Adolescent, Population, Dexamethasone, Bortezomib, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, education, Survival rate, Lenalidomide, Multiple myeloma, Aged, Salvage Therapy, education.field_of_study, business.industry, Pomalidomide, bortezomib, dexamethasone, Middle Aged, Pomalidomide, medicine.disease, Prognosis, Thalidomide, Survival Rate, Regimen, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Multiple Myeloma, 030215 immunology, medicine.drug, Follow-Up Studies
Abstract

Background As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide. Methods We did a randomised, open-label, phase 3 trial at 133 hospitals and research centres in 21 countries. We enrolled patients (aged >= 18 years) with a diagnosis of multiple myeloma and measurable disease, an Eastern Cooperative Oncology Group performance status of 0-2, who received one to three previous regimens, including a lenalidomide-containing regimen for at least two consecutive cycles. We randomly assigned patients (1:1) to bortezomib and dexamethasone with or without pomalidomide using a permutated blocked design in blocks of four, stratified according to age, number of previous regimens, and concentration of beta(2) microglobulin at screening. Bortezomib (1.3 mg/m(2)) was administered intravenously until protocol amendment 1 then either intravenously or subcutaneously on days 1,4, 8, and 11 for the first eight cycles and subsequently on days 1 and 8. Dexamethasone (20 mg [10 mg if age >75 years]) was administered orally on the same days as bortezomib and the day after. Patients allocated pomalidomide received 4 mg orally on days 1-14. Treatment cycles were every 21 days. The primary endpoint was progression-free survival in the intention-to-treat population, as assessed by an independent review committee. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered at ClinicalTrials.gov, number NCT01734928; patients are no longer being enrolled. Findings Between Jan 7, 2013, and May 15,2017,559 patients were enrolled. 281 patients were assigned pomalidomide, bortezomib, and dexamethasone and 278 were allocated bortezomib and dexamethasone. Median follow-up was 15.9 months (IQR 9.9-21.7). Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared with bortezomib and dexamethasone (median 11.20 months [95% CI 9.66-13-73] vs 7.10 months [5.88-8-48]; hazard ratio 0.61, 95% CI 0.49-0-77; p

Published
2019

24. POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

Author

Dimopoulos, M., primary, Weisel, K., additional, Moreau, P., additional, Jr, L.D.A., additional, White, D., additional, Miguel, J.S., additional, Sonneveld, P., additional, Engelhardt, M., additional, Jenner, M., additional, Corso, A., additional, Dürig, J., additional, Pavic, M., additional, Salomo, M., additional, Casal, E., additional, Jiang, R., additional, Nguyen, T., additional, Peluso, T., additional, and Richardson, P., additional

Published
2020
Full Text
View/download PDF

25. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

Author

Knip M., Akerblom H. K., Altaji E., Becker D., Bruining J., Castano L., Danne T., De Beaufort C., Dosch H. -M., Dupre J., Fraser W. D., Howard N., Ilonen J., Konrad D., Kordonouri O., Krischer J. P., Lawson M. L., Ludvigsson J., Madacsy L., Mahon J. L., Ormisson A., Palmer J. P., Pozzilli P., Savilahti E., Serrano-Rios M., Songini M., Taback S., Vaarala O., White N. H., Virtanen S. M., Wasikowa R., Mandrup-Poulsen T., Arjas E., Lernmark A., Laara E., Schmidt B., Hyytinen M., Koski K., Koski M., Merentie K., Pajakkala E., Reunanen A., Salonen M., Terhonen T., Virkkunen S., Cuthbertson D., Gainer B., Hadley D., Malloy J., Nallamshetty L., Shanker L., Bradley B., Lough G., Fraser W., Sermer M., Taback S. P., Franciscus M., Nucci A., Palmer J., Alahuhta K., Barlund S., Korhonen T., Kovanen L., Lehtonen E., Niinisto S., Pekkala M., Sorkio S., Toivanen L., Vahatalo L., Uusitalo U., Ohman T., Bongiorno R., Catteau J., Fraser G., Lloyd M., Crock P., Giles M., Siech K., See D. W., Brown C., Craig M., Johnston A., Bere L. J., Clarson C. L., Jenner M., McManus R., Renato N., Lovell M., Higo D., Kent N., Kwan J., Marshall C., Metzger D., Chanoine J. -P., Stewart L., Thompson D., Edwards A., Lange I., Mercer J., Pacaud D., Josephine H., Schwarz W., Stephure D. K., Boer J., Chatur T., Chick C., Couch B., Demianczuk N., Girgis R., Marks S., Ryan E., Thompson M., Dean H. J., Grant L., Hamelin K., LaForte J., Murphy L., Catte D., Schneider C., Sellers E. A. C., Woo V., Boland A., Clark H. D., Cooper T., Gruslin A., Karovitch A., Keely E., Malcolm J. C., Sauro V., Tawagi G. F., Andrighetti S., Arnold G., Barrett J., Blumer I., Daneman D., Donat D., Ehrlich R., Feig D., Gottesman I., Gysler M., Karkanis S., Kenshole A., Knight B., Lackie E., Lewis V., Martin M. J., Maxwell C., Oliver G., Panchum P., Shilletto N., Simone A., Skidmore M., Turrini T., Wong S., Allen C., Belanger L., Bouchard I., Ferland S., Frenette L., Garrido-Russo M., Leblanc M., Imbeault J., Morin V., Olivier G., Weisnagell J., Costain G., Dornan J., Heath K., MacSween M. -C., McGibbon A., Ramsay C., Sanderson F., Sanderson S., Benabdesselam L., Gonthier M., Huot C., Thibeault M., Laforte D., Legault L., Perron P., Armson A., Canning P., Cummings E. A., Ivanko V., McLeod L., Mokashi A., Scott K., Bridger T., Crane J., Crummell C., Curtis J. C., Dawson C., Joyce C., Newhook L. A., Newman S., Druken E., Begum-Hasan J., Breen A., Houlden R., Woods M., Carrson G., Kelly S., Martel M. J., Penner M., Sankaran K., Hardy-Brown K., King N., White R. A., Park M., Popkin J., Robson L., Coles K., Al Taji E., Cerna M., Cerny M., Francova H., Hainerova I., Kothankova H., Koukalova R., Krakorova V., Mendlova P., Sitova R., Stechova K., Vavrinec J., Vosahlo J., Zlatohlavkova B., Brazdova L., Faksova P., Gregorova D., Kantor L., Malkova K., Venhacova J., Venhacova P., Cipra A., Skvor J., Budejovice C., Tomsikova Z., Botkova-Krauseova H., Mockova A., Paterova P., Gogelova P., Kandrnalova J., Einberg U., Jakovlev U., Posiadlo S., Rannaste E., Raukas R., Riikjarv M. -A., Valla K., Astover V., Kirss A., Retpap J., Taht E., Tillmann V., Vahtra S., Heikkila M., Hirvasniemi M., Luopajarvi K., Johansson S., Kleemola P., Laukkanen E., Parkkola A., Pigg H. -M., Puttonen H., Renlund M., Salonen K., Suomalainen H., Tenkula T., Teramo K., Jarvenpaa A. -L., Hamalainen A. -M., Jussila R., Kiiveri S., Haavisto H., Holopainen S., Kupiainen H., Leeve T., Lumme K., Nironen T., Tenhola S., Tiilikainen T., Keinonen H., Lautala P., Salonen P., Vesanto M., Aspholm A. S., Asunta P., Ikavalko H., Jason E., Jaminki S., Kekki P., Koskinen M., Lehtimaki S., Lahde J., Makela M., Peltoniemi S., Poutiainen L., Ranta K., Salonsaari T., Sarviharju-Tujula S. -L., Selvenius J., Siljander H., Haanpaa P. -L., Holm C., Juutilainen A., Jarvelainen V., Kangaskolkka-Keskilohko A. -M., Laino E., Marjamaki L., Suominen E., Ylitalo S., Hokkanen M., Lounamaa R., Matikainen M., Nuuja A., Paalanen I., Puupponen A. R., Salo-Edwards H., Alanne S., Kultti T., Linjama H., Muhonen K., Vaaraniemi M., Talvitie T., Backman M., Hanhijarvi R., Koivula P., Lindstrom K., Martikainen A., Nurmi P., Bjork A., Huopio H., Komulainen J., Lehtomaki S., Muikku E., Pesola J., Sankilampi U., Arkkola T., Hekkala A., Jurvakainen S., Koivikko M. -L., Kahonen M., Leinonen E., Mykkanen T., Pohjola H., Riikonen K., Niittyvuopio A., Stenius A., Tapanainen P., Veijola R., Alar A., Jovio S., Korpela P., Makinen E., Hietanen L., Kivisto J., Kaar M. -L., Lehtimaki P., Mustila T., Popov E., Saatela S., Taittonen L., Ahtiainen K., Laaksonen N., Luoto M., Viitala J., Virransalo R., Nykanen P., Paajanen S., Parkkinen S., Pyrhonen H., Sarkka T., Aschemeier B., Bektas S., Biester T., Datz N., Deiss D., Fath M., Lupke K., Muller B., Nestoris C., Rothes S., Sadeghian E., Semler K., Arato A., Krikovszky D., Nobilis A., Szenasi J., Benevento D., Anguissola G. B., Biagioni M., Bizzarri C., Cherubini V., Ferrito L., Giordano C., Giorgetti C., Khazrai Y. M., Kyanvash S., Maddaloni E., Napoli A., Piergiovanni F., Pitocco D., Suraci T., Tabacco G., Valente L., Visalli N., Carboni M. B., Cavallo R., Cau V., Isola C., Ledda A., Loddo M., Mannu C., Pettinau M., Pisano S., Porceddu M., Putzu C., Rita A., Peters D., Schierloh U., Bisschoff M., Blonk L., Lappenschaar T., Manai B., Seesink M., Sperling-Conrad M., Verhagen M., Zoethout J. A., Basiak A., Chalas M., Chesiak M., Gramza A., Iwankiewicz J., Sieradzan E., Wikiera B., Ciechanowska M., Dziatkowiak H., Futona B., Gorska A., Glowacka-Wony M., Kaim I., Klich B., Starzyk J., Wolanin M., Tokarska L., Chucherco D., Deja G., Firek-Pedras M., Jarosz-Chobot P., Kalina M., Kutrowska-Adamusiak K., Minkina-Pedras M., Muchaka-Bianga M., Bodalski J., Mlynarski W., Szadkowska A., Cieslak A., Cypryk K., Dziatosz K., Jastzebowska J., Krysiak A., Szymanska U., Wilcznski J., Zawodniak-Szalapska M., Aguay A., Bilbao J. R., Chueca M., Cortazar A., Echarte G., Frutos T. G., Jimenez P., Martul P., Moreno A., Oyarzabal M., Rica I., Salgado Y., Martinez-Larrad M. T., Hawkins F. G., Hernandez R., Herranz L., Pallardo L. F., Deibarra L. S., Fernandez B. H., Luis J. L., Ortiz-Quintana L., Recarte P. P., Arnau D. R., Aronsson L., Boden S., Fredriksson J., Isacsson E., Johansson I., Karlsson E., Lock C., Sandstrom A. -M., Konefal M. S., Andreasson C., Dahlstrom U., Hanas R., Lundqvist K., Windell L., Jansson I., Karlsson A. -K., Lindbladh B., Odenman I., Pettersson C., Sundberg F., Sundqvist M., Aronsson S., Bellman I., Bengtsson A. -B., Lyden G. -B., Nilsson N. -O., Soderblom M., Unt C., Augustsson M., Bengtsson M., Fors H., Helmrich A., Johansson T. O., Andersson A. -C., Boiard-Stomlid A., Hellgren G., Kallsholm H., Lindqvist J., Nilsson M., Nordwall M., Stromstedt C., Ahsberg C., Lindh A., Lindhe C., Samuelsson C., Wiik A., Edenwall H., Ljumgcrantz M., Persson I. -B., Strigard E., Svensson B. -L., Aman J., Breivik G. -E., Detlofsson I. -L., Kroon M., Sarnblad S., Johansson C., Ilvered R., Lundberg A., Akesson K., Beccarelli A., Gadient M., Rappold-Amrein C., Schoenle E., Daftary A., Damagro-Elias M. E., Gilmour C., Klein M. B., Lain C., Salerno D., Smith M. E., Vats K., Pfaff D. J., Malone P., Mansfield P., Munns M., Nickel K., Pompilio K., Siemion W., Taculad R., Van Horn K., Zdanadewic M., Chambliss C., Jones J., Sadler M., Tanner-Blasiar M., Bell C., Camper N., Devaskar S., Devaskar U., Horowitz H., Rogers L., Shannahan R., Silk K., Bermudez Z., Colon R., Frazer T., Martinez-Nieves B., Torres J., Vega J., Chan M., Cook S., Goland R., Greenberg E., Jules N., Montes J., Nelson M., Parra-Valencia Z., Schachner H., Softness B., Kiviniemi M., Suomenin R., Alexander A., Hyrckowian E., Nichol L., Trucco M., Karjalainen E., Louhio T., Sarnesto A., Valtonen E., Davydova B., Helander S., Hamalainen J., Harkonen T., Joutsjoki L., Kararic M., Latva-Koivisto M., Lonn E., Nurmi T., Ollila I., Rinkinen J., Ronkainen M., Tukiainen H., Cederlof A., Kiikeri M., Tsupari S., Cheng R., Bryant K., Chan Y., Maezawa Y., Paltser G., Rasavi R., Tsui H., Winer S., Wu P., Yantha J., Pediatrics, Knip M., Akerblom H.K., Altaji E., Becker D., Bruining J., Castano L., Danne T., De Beaufort C., Dosch H.-M., Dupre J., Fraser W.D., Howard N., Ilonen J., Konrad D., Kordonouri O., Krischer J.P., Lawson M.L., Ludvigsson J., Madacsy L., Mahon J.L., Ormisson A., Palmer J.P., Pozzilli P., Savilahti E., Serrano-Rios M., Songini M., Taback S., Vaarala O., White N.H., Virtanen S.M., Wasikowa R., Mandrup-Poulsen T., Arjas E., Lernmark A., Laara E., Schmidt B., Hyytinen M., Koski K., Koski M., Merentie K., Pajakkala E., Reunanen A., Salonen M., Terhonen T., Virkkunen S., Cuthbertson D., Gainer B., Hadley D., Malloy J., Nallamshetty L., Shanker L., Bradley B., Lough G., Fraser W., Sermer M., Taback S.P., Franciscus M., Nucci A., Palmer J., Alahuhta K., Barlund S., Korhonen T., Kovanen L., Lehtonen E., Niinisto S., Pekkala M., Sorkio S., Toivanen L., Vahatalo L., Uusitalo U., Ohman T., Bongiorno R., Catteau J., Fraser G., Lloyd M., Crock P., Giles M., Siech K., See D.W., Brown C., Craig M., Johnston A., Bere L.J., Clarson C.L., Jenner M., McManus R., Renato N., Lovell M., Higo D., Kent N., Kwan J., Marshall C., Metzger D., Chanoine J.-P., Stewart L., Thompson D., Edwards A., Lange I., Mercer J., Pacaud D., Josephine H., Schwarz W., Stephure D.K., Boer J., Chatur T., Chick C., Couch B., Demianczuk N., Girgis R., Marks S., Ryan E., Thompson M., Dean H.J., Grant L., Hamelin K., LaForte J., Murphy L., Catte D., Schneider C., Sellers E.A.C., Woo V., Boland A., Clark H.D., Cooper T., Gruslin A., Karovitch A., Keely E., Malcolm J.C., Sauro V., Tawagi G.F., Andrighetti S., Arnold G., Barrett J., Blumer I., Daneman D., Donat D., Ehrlich R., Feig D., Gottesman I., Gysler M., Karkanis S., Kenshole A., Knight B., Lackie E., Lewis V., Martin M.J., Maxwell C., Oliver G., Panchum P., Shilletto N., Simone A., Skidmore M., Turrini T., Wong S., Allen C., Belanger L., Bouchard I., Ferland S., Frenette L., Garrido-Russo M., Leblanc M., Imbeault J., Morin V., Olivier G., Weisnagell J., Costain G., Dornan J., Heath K., MacSween M.-C., McGibbon A., Ramsay C., Sanderson F., Sanderson S., Benabdesselam L., Gonthier M., Huot C., Thibeault M., Laforte D., Legault L., Perron P., Armson A., Canning P., Cummings E.A., Ivanko V., McLeod L., Mokashi A., Scott K., Bridger T., Crane J., Crummell C., Curtis J.C., Dawson C., Joyce C., Newhook L.A., Newman S., Druken E., Begum-Hasan J., Breen A., Houlden R., Woods M., Carrson G., Kelly S., Martel M.J., Penner M., Sankaran K., Hardy-Brown K., King N., White R.A., Park M., Popkin J., Robson L., Coles K., Al Taji E., Cerna M., Cerny M., Francova H., Hainerova I., Kothankova H., Koukalova R., Krakorova V., Mendlova P., Sitova R., Stechova K., Vavrinec J., Vosahlo J., Zlatohlavkova B., Brazdova L., Faksova P., Gregorova D., Kantor L., Malkova K., Venhacova J., Venhacova P., Cipra A., Skvor J., Budejovice C., Tomsikova Z., Botkova-Krauseova H., Mockova A., Paterova P., Gogelova P., Kandrnalova J., Einberg U., Jakovlev U., Posiadlo S., Rannaste E., Raukas R., Riikjarv M.-A., Valla K., Astover V., Kirss A., Retpap J., Taht E., Tillmann V., Vahtra S., Heikkila M., Hirvasniemi M., Luopajarvi K., Johansson S., Kleemola P., Laukkanen E., Parkkola A., Pigg H.-M., Puttonen H., Renlund M., Salonen K., Suomalainen H., Tenkula T., Teramo K., Jarvenpaa A.-L., Hamalainen A.-M., Jussila R., Kiiveri S., Haavisto H., Holopainen S., Kupiainen H., Leeve T., Lumme K., Nironen T., Tenhola S., Tiilikainen T., Keinonen H., Lautala P., Salonen P., Vesanto M., Aspholm A.S., Asunta P., Ikavalko H., Jason E., Jaminki S., Kekki P., Koskinen M., Lehtimaki S., Lahde J., Makela M., Peltoniemi S., Poutiainen L., Ranta K., Salonsaari T., Sarviharju-Tujula S.-L., Selvenius J., Siljander H., Haanpaa P.-L., Holm C., Juutilainen A., Jarvelainen V., Kangaskolkka-Keskilohko A.-M., Laino E., Marjamaki L., Suominen E., Ylitalo S., Hokkanen M., Lounamaa R., Matikainen M., Nuuja A., Paalanen I., Puupponen A.R., Salo-Edwards H., Alanne S., Kultti T., Linjama H., Muhonen K., Vaaraniemi M., Talvitie T., Backman M., Hanhijarvi R., Koivula P., Lindstrom K., Martikainen A., Nurmi P., Bjork A., Huopio H., Komulainen J., Lehtomaki S., Muikku E., Pesola J., Sankilampi U., Arkkola T., Hekkala A., Jurvakainen S., Koivikko M.-L., Kahonen M., Leinonen E., Mykkanen T., Pohjola H., Riikonen K., Niittyvuopio A., Stenius A., Tapanainen P., Veijola R., Alar A., Jovio S., Korpela P., Makinen E., Hietanen L., Kivisto J., Kaar M.-L., Lehtimaki P., Mustila T., Popov E., Saatela S., Taittonen L., Ahtiainen K., Laaksonen N., Luoto M., Viitala J., Virransalo R., Nykanen P., Paajanen S., Parkkinen S., Pyrhonen H., Sarkka T., Aschemeier B., Bektas S., Biester T., Datz N., Deiss D., Fath M., Lupke K., Muller B., Nestoris C., Rothes S., Sadeghian E., Semler K., Arato A., Krikovszky D., Nobilis A., Szenasi J., Benevento D., Anguissola G.B., Biagioni M., Bizzarri C., Cherubini V., Ferrito L., Giordano C., Giorgetti C., Khazrai Y.M., Kyanvash S., Maddaloni E., Napoli A., Piergiovanni F., Pitocco D., Suraci T., Tabacco G., Valente L., Visalli N., Carboni M.B., Cavallo R., Cau V., Isola C., Ledda A., Loddo M., Mannu C., Pettinau M., Pisano S., Porceddu M., Putzu C., Rita A., Peters D., Schierloh U., Bisschoff M., Blonk L., Lappenschaar T., Manai B., Seesink M., Sperling-Conrad M., Verhagen M., Zoethout J.A., Basiak A., Chalas M., Chesiak M., Gramza A., Iwankiewicz J., Sieradzan E., Wikiera B., Ciechanowska M., Dziatkowiak H., Futona B., Gorska A., Glowacka-Wony M., Kaim I., Klich B., Starzyk J., Wolanin M., Tokarska L., Chucherco D., Deja G., Firek-Pedras M., Jarosz-Chobot P., Kalina M., Kutrowska-Adamusiak K., Minkina-Pedras M., Muchaka-Bianga M., Bodalski J., Mlynarski W., Szadkowska A., Cieslak A., Cypryk K., Dziatosz K., Jastzebowska J., Krysiak A., Szymanska U., Wilcznski J., Zawodniak-Szalapska M., Aguay A., Bilbao J.R., Chueca M., Cortazar A., Echarte G., Frutos T.G., Jimenez P., Martul P., Moreno A., Oyarzabal M., Rica I., Salgado Y., Martinez-Larrad M.T., Hawkins F.G., Hernandez R., Herranz L., Pallardo L.F., Deibarra L.S., Fernandez B.H., Luis J.L., Ortiz-Quintana L., Recarte P.P., Arnau D.R., Aronsson L., Boden S., Fredriksson J., Isacsson E., Johansson I., Karlsson E., Lock C., Sandstrom A.-M., Konefal M.S., Andreasson C., Dahlstrom U., Hanas R., Lundqvist K., Windell L., Jansson I., Karlsson A.-K., Lindbladh B., Odenman I., Pettersson C., Sundberg F., Sundqvist M., Aronsson S., Bellman I., Bengtsson A.-B., Lyden G.-B., Nilsson N.-O., Soderblom M., Unt C., Augustsson M., Bengtsson M., Fors H., Helmrich A., Johansson T.O., Andersson A.-C., Boiard-Stomlid A., Hellgren G., Kallsholm H., Lindqvist J., Nilsson M., Nordwall M., Stromstedt C., Ahsberg C., Lindh A., Lindhe C., Samuelsson C., Wiik A., Edenwall H., Ljumgcrantz M., Persson I.-B., Strigard E., Svensson B.-L., Aman J., Breivik G.-E., Detlofsson I.-L., Kroon M., Sarnblad S., Johansson C., Ilvered R., Lundberg A., Akesson K., Beccarelli A., Gadient M., Rappold-Amrein C., Schoenle E., Daftary A., Damagro-Elias M.E., Gilmour C., Klein M.B., Lain C., Salerno D., Smith M.E., Vats K., Pfaff D.J., Malone P., Mansfield P., Munns M., Nickel K., Pompilio K., Siemion W., Taculad R., Van Horn K., Zdanadewic M., Chambliss C., Jones J., Sadler M., Tanner-Blasiar M., Bell C., Camper N., Devaskar S., Devaskar U., Horowitz H., Rogers L., Shannahan R., Silk K., Bermudez Z., Colon R., Frazer T., Martinez-Nieves B., Torres J., Vega J., Chan M., Cook S., Goland R., Greenberg E., Jules N., Montes J., Nelson M., Parra-Valencia Z., Schachner H., Softness B., Kiviniemi M., Suomenin R., Alexander A., Hyrckowian E., Nichol L., Trucco M., Karjalainen E., Louhio T., Sarnesto A., Valtonen E., Davydova B., Helander S., Hamalainen J., Harkonen T., Joutsjoki L., Kararic M., Latva-Koivisto M., Lonn E., Nurmi T., Ollila I., Rinkinen J., Ronkainen M., Tukiainen H., Cederlof A., Kiikeri M., Tsupari S., Cheng R., Bryant K., Chan Y., Maezawa Y., Paltser G., Rasavi R., Tsui H., Winer S., Wu P., Yantha J., University of Zurich, and Knip, Mikael

Subjects
Male, Risk, medicine.medical_specialty, Casein, Breastfeeding, 030209 endocrinology & metabolism, 610 Medicine & health, 2700 General Medicine, Endocrinology and Diabetes, Disease-Free Survival, law.invention, Follow-Up Studie, Nutrition Policy, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, SDG 3 - Good Health and Well-being, law, Internal medicine, Diabetes mellitus, medicine, Humans, Cumulative incidence, 030212 general & internal medicine, Child, Infant Nutritional Physiological Phenomena, Original Investigation, 2. Zero hunger, Type 1 diabetes, business.industry, Hazard ratio, Absolute risk reduction, Infant, Newborn, Caseins, General Medicine, ta3121, medicine.disease, Infant Formula, 3. Good health, Diabetes Mellitus, Type 1, Infant formula, 10036 Medical Clinic, Endokrinologi och diabetes, Female, business, Human, Follow-Up Studies
Abstract

IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the extensively hydrolyzed casein formula and 1078 to a conventional formula. The follow-up of the participants ended on February 28, 2017. INTERVENTIONS The participants received either a casein hydrolysate or a conventional adapted cows milk formula supplemented with 20% of the casein hydrolysate. The minimum duration of study formula exposure was 60 days by 6 to 8 months of age. MAIN OUTCOMES AND MEASURES Primary outcome was type 1 diabetes diagnosed according to World Health Organization criteria. Secondary outcomes included age at diabetes diagnosis and safety (adverse events). RESULTS Among 2159 newborn infants (1021 female [47.3%]) who were randomized, 1744 (80.8%) completed the trial. The participants were observed for a median of 11.5 years (quartile [Q] 1-Q3, 10.2-12.8). The absolute risk of type 1 diabetes was 8.4% among those randomized to the casein hydrolysate (n = 91) vs 7.6% among those randomized to the conventional formula (n = 82) (difference, 0.8%[95% CI, -1.6% to 3.2%]). The hazard ratio for type 1 diabetes adjusted for human leukocyte antigen risk group, duration of breastfeeding, duration of study formula consumption, sex, and region while treating study center as a random effect was 1.1 (95% CI, 0.8 to 1.5; P = .46). The median age at diagnosis of type 1 diabetes was similar in the 2 groups (6.0 years [Q1-Q3, 3.1-8.9] vs 5.8 years [Q1-Q3, 2.6-9.1]; difference, 0.2 years [95% CI, -0.9 to 1.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). CONCLUSIONS AND RELEVANCE Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 1 diabetes. Funding Agencies|Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [HD040364, HD042444, HD051997]; Canadian Institutes of Health Research; Commission of the European Communities [QLK1-2002-00372]; European Foundation for the Study of Diabates/JDRF/Novo Nordisk; Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research) [250114]; Dutch Diabetes Research Foundation; Finnish Diabetes Research Foundation; JDRF

Published
2018

28. Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma

Author

Ahmedzai, SH, Snowden, JA, Ashcroft, AJ, Cairns, DA, Williams, C, Hockaday, A, Cavenagh, JD, Ademokun, D, Tholouli, E, Allotey, D, Dhanapal, V, Jenner, M, Yong, K, Cavet, J, Hunter, H, Bird, JM, Pratt, G, Parrish, C, Brown, JM, Morris, TCM, Cook, G, and NCRI Haemato-Oncology Clinical Studies Group

Subjects
humanities
Abstract

PURPOSE: Salvage autologous stem-cell transplantation (sASCT) in patients with multiple myeloma (MM) relapsing after a prior autologous stem-cell transplantation leads to increased remission duration and overall survival. We report a comprehensive study on patient-reported outcomes, including quality of life (QoL) and pain in sASCT. \ud \ud \ud \ud METHODS: Patients were randomly assigned to either sASCT or nontransplantation consolidation (NTC). Pain and QoL were assessed as secondary outcomes using validated QoL instruments (European Organisation for Research and Treatment of Cancer QLQ-C30 and myeloma-specific module, QLQ-MY20; the Brief Pain Inventory [Short Form]; and the Leeds Assessment of Neuropathic Symptoms and Signs [Self-Assessment] scale). \ud \ud \ud \ud RESULTS: A total of 288 patients (> 96%) consented to the QoL substudy. The median follow-up was 52 months. The European Organisation for Research and Treatment of Cancer QLQ-C30 Global health status scores were higher (better) in the NTC group at 100 days after random assignment ( P = .0496), but not at later time points. Pain interference was higher (worse) in the sASCT group than in the NTC group at 6 months after random assignment ( P = .0267), with patients with sASCT reporting higher scores for Pain interference with daily living for up to 2 years after random assignment. Patients reporting lower concerns about adverse effects of treatment after sASCT had a time to progression advantage. \ud \ud \ud \ud CONCLUSION: Patients with sASCT with relapsed MM demonstrated a comparative reduction in QoL and greater impact of treatment adverse effects lasting for 6 months and up to 2 years for pain, after which patients who had received sASCT reported better outcomes. Patients who experienced lower adverse effects after sASCT had longer time to progression and overall survival, showing the need to improve symptom management peritransplantation. To our knowledge, this study provides the most comprehensive picture of QoL before and after sASCT in patients with relapsed MM.

Published
2019

29. Southern Hemisphere Breeding Stock D humpback whale population estimates from North West Cape, Western Australia

Author

Kent, C. S., Jenner, C., Jenner, M., Phil Bouchet, and Rexstad, E.

Subjects
bepress|Life Sciences, Animal Science and Zoology, MarXiv|Life Sciences|Ecology and Evolutionary Biology, Aquatic Science, bepress|Life Sciences|Marine Biology, MarXiv|Life Sciences, MarXiv|Life Sciences|Marine Biology, bepress|Life Sciences|Ecology and Evolutionary Biology|Population Biology, bepress|Life Sciences|Ecology and Evolutionary Biology, Ecology, Evolution, Behavior and Systematics, MarXiv|Life Sciences|Ecology and Evolutionary Biology|Population Biology
Abstract

Estimates of the abundance of Breeding Stock D humpback whales (Megaptera novaeangliae) are key to the conservation and management of what is thought to be one of the largest populations of the species. Five years (2000, 2001, 2006, 2007 and 2008) of aerial surveys carried out over an eight-year period at North West Cape (Western Australia) using line transect methodology allowed trends in whale numbers to be investigated, and provided a base for comparison with estimates made approximately 400km south at Shark Bay (Western Australia). A total of 3,127 whale detections were made during 74 surveys of the 7,043km2 study area west of NWC. Pod abundance for each flight was computed using a HorvitzThompson like estimator and converted to an absolute measure of abundance after corrections were made for estimated mean cluster size, unsurveyed time, swimming speed and animal availability. Resulting estimates from the migration model of best fit with the most credible assumptions were 7,276 (CI = 4,993–10,167) for 2000, 12,280 (CI = 6,830–49,434) for 2001, 18,692 (CI = 12,980–24,477) for 2006, 20,044 (CI = 13,815–31,646) for 2007, and 26,100 (CI = 20,152–33,272) for 2008. Based on these data, the trend model with the greatest r2 was exponential with an annual increase rate of 13% (CI = 5.6%–18.1%). While this value is above the species’ estimated maximum plausible growth rate of 11.8%, it is reasonably close to previous reports of between 10–12%. The coefficient of variation, however, was too large for a reliable trend estimate. Perception bias was also not accounted for in these calculations. Based on a crude appraisal which yielded an estimated p(0) of 0.783 (from independent observer effort, CV = 0.973), the 2008 humpback population size may be as large as 33,300. In conclusion, the work here provides evidence of an increasing Breeding Stock D population, but further surveys are necessary to confirm whether the population is indeed increasing at its maximum rate.

Published
2019

30. Growth Hormone Supplementation and Psychosocial Functioning to Adult Height in Turner Syndrome: A Questionnaire Study of Participants in the Canadian Randomized Trial

Author

Rovet, Joanne F., Van Vliet, Guy, Curtis, J. A., Cummings, E., Salisbury, S. R., Szots, F., Khoury, K., Collu, R., Deal, C. L., Huot, C., Barnes, R. D., Guyda, H. J., Legault, L., Polychronakos, C., Rodd, C., Faught, K. A., Lawrence, S. E., Lawson, M. L., Alexander, D. S., Daneman, D., Bailey, J. D., Ehrlich, R. M., Perlman, K., Sochett, E., MacMillan, A. B., Holland, F. J., Vander Meulen, J. A., Clarson, C. L., and Jenner, M. R.F.

Subjects
0301 basic medicine, Coping (psychology), Endocrinology, Diabetes and Metabolism, Turner syndrome, Self-concept, 030209 endocrinology & metabolism, lcsh:Diseases of the endocrine glands. Clinical endocrinology, Psychosocial functioning, law.invention, Correlation, 03 medical and health sciences, Endocrinology, 0302 clinical medicine, Randomized controlled trial, law, Behavior problems, Medicine, Growth hormone, Original Research, lcsh:RC648-665, business.industry, medicine.disease, Social relation, self-concept, behavior problems, 030104 developmental biology, growth hormone, Social competence, psychosocial functioning, business, Psychosocial, Clinical psychology
Abstract

Despite the long-held belief that growth hormone supplementation provides psychosocial benefits to patients with Turner syndrome (TS), this assumption has never been rigorously tested in a randomized control trial. As a sub-study of the Canadian growth-hormone trial, parent-, and patient-completed standardized questionnaires were used to compare 70 girls with TS who received injections (GH group) and 61 similarly followed untreated TS controls (C) on multiple facets of psychosocial functioning. Questionnaires were given (i) at baseline (session 1, mean age = 10.4 y), (ii) before estrogen therapy for puberty induction (session 2, mean age = 13.0 y), (iii) after 1 year of estrogen therapy (session 3, mean age = 14.4 y), and (iv) when growth stopped (session 4, mean age = 16.3 y). Groups were compared for multiple facets of psychosocial function within social, behavioral, self-esteem, and academic domains. Results were also correlated with indices of adult height. We found no global (i.e., across-session) group differences on any scales or subscales of the four domains. In both GH and C groups, age-related improvements were seen for social problems, externalizing behavior problems, and school functioning and age-related declines for social competence and social relations. Both parents and patients claimed GH received less teasing than C but C had more friends than GH. Results from analyses conducted within individual sessions showed that while GH at early sessions claimed to be more popular, more socially engaged, better adapted, and to have higher self-esteem than C, C was reported to be less anxious, depressed, and withdrawn than GH at adult height. The correlation analyses revealed different effects of adult height and height gain on outcome for the two groups. In GH, both height parameters were correlated with multiple parent- and/or self-reported indices from the four psychosocial domains, whereas in C, only adult height and two indices (viz., total self-concept and school functioning), were correlated. The observed modest gains in psychosocial functioning for patients with TS treated with GH highlight the need for alternative approaches to assist them in coping with the challenges of their condition.

Published
2019

31. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Richardson, P.G. Oriol, A. Beksac, M. Liberati, A.M. Galli, M. Schjesvold, F. Lindsay, J. Weisel, K. White, D. Facon, T. San Miguel, J. Sunami, K. O'Gorman, P. Sonneveld, P. Robak, P. Semochkin, S. Schey, S. Yu, X. Doerr, T. Bensmaine, A. Biyukov, T. Peluso, T. Zaki, M. Anderson, K. Dimopoulos, M. Abildgaard, N. Adler, H. Altuntas, F. Akay, O.M. Amin, B. Anagnostopoulos, A. Anderson, L. Anttila, P. Araujo, C. Arce-Lara, C. Aydin, Y. Basu, S. Battini, R. Beeker, T. Benboubker, L. Ben-Yehuda, D. Bladé, J. Blau, I.W. Boccia, R. Burke, L. Byeff, P. Cascavilla, N. Cavo, M. Chantry, A. Charles, Y. Chaudhry, A. Corso, A. Coyne, M. De Arriba, F. Delimpasi, S. Desjardins, P. Dhakal, B. Di Bartolomeo, P. Di Raimondo, F. Dürig, J. Engelhardt, M. Escoffre-Barbe, M. Esteves, G. Flogegard, M. Gabrail, N. Gamberi, B. Garrison, M. Gay, J. Gisslinger, H. Goldschmidt, H. Goncalves, C. Gressot, L. Grosicki, S. Hanna, W. Hayden, P. Henriques Bernardo, M.M. Hermann, R. Holden, V. Honkalehto, K. Huben, M. Huffman, J. Hunter, H. Hus, M. Jagasia, M. Jagganath, S. Janakiram, M. Jaiyesimi, I. Jenner, M. João, C. Johnson, P. Jurcyszyn, A. Kalayoğlu Beşişik, S. Kambhampati, S. Kanate, A. Karadoğan, I. Khojasteh, A. Kirkel, D. Komarnicki, M. Krauth, M.-T. Kuriakose, P. Larocca, A. Lauri, B. Leleu, X. Lucio, P. Luppi, M. Mangiacavalli, S. Mariette, C. Matsue, K. Mellqvist, U.-H. Mendeleeva, L. Meshad, M. Miller, C. Mohrbacher, A. Moreau, P. Morelli, A.M. Müldür, E. Naassan, A. Nahi, H. Nair, R. O'Dwyer, M. Öngören Aydin, S. Openshaw, T. O'Rourke, T. Osswald, M. Overton, L. Pati, A. Pavic, M. Pegourie, B. Pehlivan, M. Pierola, A.A. Plesner, T. Pluta, A. Rabin, N. Ramasamy, K. Rambaldi, A. Rodriguez, P. Röllig, C. Rosenblatt, J. Rosenbluth, J. Salomo, M. Samoylova, O. Sastre Moral, J. Sati, H. Selleri, C. Shafeek, S. Shinagawa, A. Sleckman, B. Smith, C. Sonmez, M. Stone, C. Streetly, M. Suzuki, K. Taetle, R. Tafuri, A. Takezako, N. Teke, H.Ü. Vapaatalo, M. Vassilopoulos, G. Verma, A. Vidito, S. Viterbo, L. Vural, F. Wang, X.S. Yağci, M. Yee, A. OPTIMISMM trial investigators

Subjects
hemic and lymphatic diseases
Abstract

Background: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide. Methods: We did a randomised, open-label, phase 3 trial at 133 hospitals and research centres in 21 countries. We enrolled patients (aged ≥18 years)with a diagnosis of multiple myeloma and measurable disease, an Eastern Cooperative Oncology Group performance status of 0–2, who received one to three previous regimens, including a lenalidomide-containing regimen for at least two consecutive cycles. We randomly assigned patients (1:1)to bortezomib and dexamethasone with or without pomalidomide using a permutated blocked design in blocks of four, stratified according to age, number of previous regimens, and concentration of β2 microglobulin at screening. Bortezomib (1·3 mg/m2)was administered intravenously until protocol amendment 1 then either intravenously or subcutaneously on days 1, 4, 8, and 11 for the first eight cycles and subsequently on days 1 and 8. Dexamethasone (20 mg [10 mg if age >75 years])was administered orally on the same days as bortezomib and the day after. Patients allocated pomalidomide received 4 mg orally on days 1–14. Treatment cycles were every 21 days. The primary endpoint was progression-free survival in the intention-to-treat population, as assessed by an independent review committee. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered at ClinicalTrials.gov, number NCT01734928; patients are no longer being enrolled. Findings: Between Jan 7, 2013, and May 15, 2017, 559 patients were enrolled. 281 patients were assigned pomalidomide, bortezomib, and dexamethasone and 278 were allocated bortezomib and dexamethasone. Median follow-up was 15·9 months (IQR 9·9–21·7). Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared with bortezomib and dexamethasone (median 11·20 months [95% CI 9·66–13·73]vs 7·10 months [5·88–8·48]; hazard ratio 0·61, 95% CI 0·49–0·77; p

Published
2019

33. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author

Dimopoulos, M.A. Gay, F. Schjesvold, F. Beksac, M. Hajek, R. Weisel, K.C. Goldschmidt, H. Maisnar, V. Moreau, P. Min, C.K. Pluta, A. Chng, W.-J. Kaiser, M. Zweegman, S. Mateos, M.-V. Spencer, A. Iida, S. Morgan, G. Suryanarayan, K. Teng, Z. Skacel, T. Palumbo, A. Dash, A.B. Gupta, N. Labotka, R. Rajkumar, S.V. Bar, D. Basso, A. Fantl, D. He, S. Horvath, N. Lee, C. Rowlings, P. Taylor, K. Cochrane, T. Kwok, F. Ramanathan, S. Agis, H. Zojer, N. Kentos, A. Offner, F. Van Droogenbroeck, J. Wu, K.L. Maiolino, A. Martinez, G. Zanella, K. Capra, M. Araújo, S. Gregora, E. Pour, L. Scudla, V. Spicka, I. Abildgaard, N. Andersen, N. Jensen, B.A. Helleberg, C. Plesner, T. Salomo, M. Svirskaite, A. Delarue, R. Blau, I. Schieferdecker, A. Teleanu, V. Munder, M. Röllig, C. Salwender, H.-J. Fuhrmann, S. Weisel, K. Duerig, J. Zeis, M. Klein, S. Reimer, P. Schmidt, C. Scheid, C. Mayer, K. Hoffmann, M. Sosada, M. Dimopoulos, A. Delimpasi, S. Kyrtsonis, M.-C. Anagnostopoulos, A. Nagy, Z. Illés, Á. Egyed, M. Borbényi, Z. Mikala, G. Dally, N. Horowitz, N. Gutwein, O. Nemets, A. Vaxman, I. Shvetz, O. Trestman, S. Ruchlemer, R. Nagler, A. Tadmor, T. Rouvio, O. Preis, M. Cavo, M. De Rosa, L. Musto, P. Cafro, A. Tosi, P. Offidani, M. Corso, A. Rossi, G. Liberati, A.M. Bosi, A. Suzuki, K. Nakaseko, C. Ishikawa, T. Matsumoto, M. Nagai, H. Sunami, K. Chou, T. Akashi, K. Takezako, N. Hagiwara, S. Eom, H.S. Jo, D.-Y. Kim, J.S. Lee, J.H. Yoon, S.S. Yoon, D.H. Kim, K. Levin, M.-D. Vellenga, E. Minnema, M. Waage, A. Haukås, E. Grosicki, S. Pluta, A. Robak, T. Marques, H. Bergantim, R. Campilho, F. Chng, W.J. Goh, Y.T. McDonald, A. Rapoport, B. Álvarez Rivas, M.A. De Arriba de La Fuente, F. González Montes, Y. Martin Sanchez, J. Mateos, M.V. Oriol Rocafiguera, A. Rosinol, L. San Miguel, J. Pérez de Oteyza, J. Encinas, C. Alegre-Amor, A. López-Guía, A. Axelsson, P. Carlson, K. Stromberg, O. Hansson, M. Hveding Blimark, C. Mueller, R. Chen, C.-C. Liu, T.-C. Huang, S.-Y. Wang, P.-N. Na Nakorn, T. Prayongratana, K. Unal, A. Goker, H. Sonmez, M. Korenkova, S. Chaidos, A. Oakervee, H. Sati, H. Benjamin, R. Wechalekar, A. Garg, M. Ramasamy, K. Cook, G. Chantry, A. Jenner, M. Buadi, F. Berryman, R. Janakiram, M. TOURMALINE-MM3 study group

Abstract

Background: Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. Methods: The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed diagnosis of symptomatic multiple myeloma according to International Myeloma Working Group criteria who had achieved at least a partial response after undergoing standard-of-care induction therapy followed by high-dose melphalan (200 mg/m2) conditioning and single ASCT within 12 months of diagnosis. Patients were randomly assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles for 2 years following induction, high-dose therapy, and transplantation. The initial 3 mg dose was increased to 4 mg from cycle 5 if tolerated during cycles 1–4. Randomisation was stratified by induction regimen, pre-induction disease stage, and response post-transplantation. The primary endpoint was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed in all patients who received at least one dose of ixazomib or placebo, according to treatment actually received. This trial is registered with ClinicalTrials.gov, number NCT02181413, and follow-up is ongoing. Findings: Between July 31, 2014, and March 14, 2016, 656 patients were enrolled and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261). With a median follow-up of 31 months (IQR 27·3–35·7), we observed a 28% reduction in the risk of progression or death with ixazomib versus placebo (median PFS 26·5 months [95% CI 23·7–33·8] vs 21·3 months [18·0–24·7]; hazard ratio 0·72, 95% CI 0·58–0·89; p=0·0023). No increase in second malignancies was noted with ixazomib therapy (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients in the ixazomib group and 51 (20%) of 259 patients in the placebo group experienced serious adverse events. During the treatment period, one patient died in the ixazomib group and none died in the placebo group. Interpretation: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma. Funding: Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company. © 2019 Elsevier Ltd

Published
2019

37. Song variation of the South Eastern Indian Ocean pygmy blue whale population in the Perth Canyon, Western Australia

Author

Jolliffe, C., McCauley, Robert, Gavrilov, Alexander, Jenner, C., Jenner, M., Duncan, Alec, Jolliffe, C., McCauley, Robert, Gavrilov, Alexander, Jenner, C., Jenner, M., and Duncan, Alec

Abstract

Sea noise collected over 2003 to 2017 from the Perth Canyon, Western Australia was analysed for variation in the South Eastern Indian Ocean pygmy blue whale song structure. The primary song-types were: P3, a three unit phrase (I, II and III) repeated with an inter-song interval (ISI) of 170–194 s; P2, a phrase consisting of only units II & III repeated every 84–96 s; and P1 with a phrase consisting of only unit II repeated every 45–49 s. The different ISI values were approximate multiples of each other within a season. When comparing data from each season, across seasons, the ISI value for each song increased significantly through time (all fits had p < 0.001), at 0.30 s/Year (95%CI 0.217–0.383), 0.8 s/Year (95% CI 0.655–1.025) and 1.73 s/Year (95%CI 1.264–2.196) for the P1, P2 and P3 songs respectively. The proportions of each song-type averaged at 21.5, 24.2 and 56% for P1, P2 and P3 occurrence respectively and these ratios could vary by up to ± 8% (95% CI) amongst years. On some occasions animals changed the P3 ISI to be significantly shorter (120–160 s) or longer (220–280 s). Hybrid song patterns occurred where animals combined multiple phrase types into a repeated song. In recent years whales introduced further complexity by splitting song units. This variability of song-type and proportions implies abundance measure for this whale sub population based on song detection needs to factor in trends in song variability to make data comparable between seasons. Further, such variability in song production by a sub population of pygmy blue whales raises questions as to the stability of the song types that are used to delineate populations. The high level of song variability may be driven by an increasing number of background whale callers creating ‘noise’ and so forcing animals to alter song in order to ‘stand out’ amongst the crowd.

Published
2019

39. Playskin Lift: Development and Initial Testing of an Exoskeletal Garment to Assist Upper Extremity Mobility and Function

Author

Huantian Cao, Michele A. Lobo, Jenner M. Buckley, James C. Galloway, Martha L. Hall, Jill S. Higginson, Ozan Erol, and John Koshy

Subjects
Male, 030506 rehabilitation, medicine.medical_specialty, Activities of daily living, Technical Reports, media_common.quotation_subject, Physical Therapy, Sports Therapy and Rehabilitation, Clothing, Upper Extremity, 03 medical and health sciences, 0302 clinical medicine, Human–computer interaction, Activities of Daily Living, medicine, Humans, Toddler, Function (engineering), Self-Help Devices, media_common, Arthrogryposis, Lift (data mining), Infant, Equipment Design, Disabled Children, Designtheory, Physical therapy, Technical report, 0305 other medical science, Engineering design process, Psychology, 030217 neurology & neurosurgery, Gravitation
Abstract

BackgroundA person's ability to move his or her arms against gravity is important for independent performance of critical activities of daily living and for exploration that facilitates early cognitive, language, social, and perceptual-motor development. Children with a variety of diagnoses have difficulty moving their arms against gravity.ObjectiveThe purpose of this technical report is to detail the design process and initial testing of a novel exoskeletal garment, the Playskin Lift, that assists and encourages children to lift their arms against gravity.DesignThis report details the design theory and process, the device, and the results of field testing with a toddler with impaired upper extremity function due to arthrogryposis multiplex congenita.ResultsThe Playskin Lift is an inexpensive (LimitationsThis report details initial testing with one child. Future testing with more participants is recommended.ConclusionsThese results suggest that by considering the broad needs of users, including cost, accessibility, comfort, aesthetics, and function, we can design inexpensive devices that families and clinicians can potentially fabricate in their own communities to improve function, participation, exploration, and learning for children with disabilities.

Published
2016

40. S873 EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK

Author

Pawlyn, C., primary, Kaiser, M., additional, Davies, F., additional, Cairns, D., additional, Striha, A., additional, Hockaday, A., additional, Kishore, B., additional, Garg, M., additional, Williams, C., additional, Karunanithi, K., additional, Lindsay, J., additional, Jones, J., additional, Jenner, M., additional, Russell, N., additional, Cook, G., additional, Drayson, M., additional, Owen, R., additional, Gregory, W., additional, Morgan, G., additional, and Jackson, G., additional

Published
2019
Full Text
View/download PDF

41. PF629 CONSOLIDATION FOLLOWING INFUSIONAL DPACE IMPROVES OUTCOMES IN NOVEL AGENT RELAPSED/REFRACTORY MYELOMA PATIENTS

Author

Djebbari, F., primary, Deabrew, K., additional, Salhan, B., additional, Panitsas, F., additional, Goodwin, E., additional, Willan, J., additional, Sternberg, A., additional, Maouche, N., additional, Vallance, G., additional, Moore, S., additional, Ramasamy, K., additional, Basu, S., additional, Jenner, M., additional, and Kothari, J., additional

Published
2019
Full Text
View/download PDF

42. PF595 POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE-PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

Author

Dimopoulos, M., primary, Weisel, K., additional, Moreau, P., additional, Jr, L.D. Anderson, additional, White, D., additional, Miguel, J. San, additional, Sonneveld, P., additional, Engelhardt, M., additional, Jenner, M., additional, Corso, A., additional, Dürig, J., additional, Pavic, M., additional, Salomo, M., additional, Yu, X., additional, Nguyen, T. Vi, additional, Bensmaine, A., additional, Peluso, T., additional, Zaki, M., additional, and Richardson, P., additional

Published
2019
Full Text
View/download PDF

46. Water temperature correlates with baleen whale foraging behaviour at multiple scales in the Antarctic

Author

Owen, K., Jenner, K.C.S., Jenner, M.-N.M., McCauley, R.D., Andrews, R.D., Owen, K., Jenner, K.C.S., Jenner, M.-N.M., McCauley, R.D., and Andrews, R.D.

Abstract

How baleen whales locate prey and how environmental change may influence whale foraging success are not well understood. Baleen whale foraging habitat has largely been described at a population level, yet population responses to change are the result of individual strategies across multiple scales. This study aimed to determine how the foraging behaviour of individual whales varied relative to environmental conditions along their movement path. Biotelemetry devices provided information on humpback whale (Megaptera novaeangliae) movement at two spatial scales in East Antarctica, and a mixed modelling approach was used at a medium scale (tens of kilometres) to determine which environmental factors correlated with a change in foraging behaviour. Water temperature was linked to a change in foraging behaviour at both spatial scales. At the medium scale, warmer water was associated with the resident state, commonly assumed to represent periods of foraging behaviour. However, fine-scale analyses suggested that cooler water was associated with a higher feeding rate. Variation in whale foraging behaviour with changes in water temperature adds support to the hypothesis that whales may be able to track environmental conditions to find prey. Future research should investigate this pattern further, given the predicted rise in water temperatures under climate-change scenarios.

Published
2018

47. Habitat associations of cetaceans and seabirds in the tropical eastern Indian Ocean

Author

Sutton, A.L., Jenner, K.C.S., Jenner, M-N M., Sutton, A.L., Jenner, K.C.S., and Jenner, M-N M.

Abstract

There is an increasing demand for integrated pelagic surveys to support ecosystem-based management of marine environments and their associated marine life. The Browse Basin in the tropical eastern Indian Ocean was surveyed using ship line transects to determine habitat associations of cetaceans and seabirds with submarine topography and local oceanographic conditions during winter and spring 2008. Fourteen species of cetaceans, including the data deficient pygmy blue whale, and 23 species of seabirds were encountered throughout the basin. Aggregations of both cetaceans and seabirds were observed at two significant submarine topographic features, Scott Reef and Browse Cliffs, particularly during spring when encounters and abundances of odontocetes were far greater. The attraction of cetaceans and seabirds to Scott Reef and Browse Cliffs was likely foraging-related given these features were associated with upwelling and elevated biomass of krill and fish. Sub-mesoscale sea surface temperature and chlorophyll a fronts also occurred in vicinity to Browse Cliffs and the shelf environment. The Browse Basin is an important, and potentially predictable, foraging ground for a variety of top predators, and their occurrence would have implications for the current and future management practices of oil and gas industries operating in the region.

Published
2018

48. FactCheck: do bank profits ‘belong to everyday Australians’?

Author

Humphrey-Jenner, M., Hodgson, Helen, Humphrey-Jenner, M., and Hodgson, Helen

Abstract

The Australian Banking Association says 'nearly 80% of bank profits go straight back to shareholders', the majority of whom are 'everyday Australians'. Is that right?

Published
2018

49. Environmental evidence for a pygmy blue whale aggregation area in the Subtropical Convergence Zone south of Australia

Author

Garcia-Rojas, M., Jenner, K., Gill, P., Jenner, M., Sutton, A., McCauley, Robert, Garcia-Rojas, M., Jenner, K., Gill, P., Jenner, M., Sutton, A., and McCauley, Robert

Abstract

© 2018 Society for Marine Mammalogy. The importance of the Subtropical Convergence Zone south of Australia as a feeding area to the pygmy blue whale of the eastern Indian Ocean was investigated to better understand migration patterns and habitat use. A combination of satellite tagging studies during 2003-2005 and acoustic and visual surveys during the austral summer of 2013 confirmed the presence of pygmy blue whales in the Subtropical Convergence Zone and provided evidence for feeding throughout the region. Of the 67 pygmy blue whales acoustically detected, many were localized in proximity to sea surface temperature fronts and high chlorophyll concentrations, which could be a behavioral strategy to attract conspecifics to good feeding sites. Aggregations of up to four pygmy blue whales, along with decreased call rates during the day, may suggest feeding despite no direct observations of pygmy blue whales consuming euphausiids. The oceanographic features present throughout the Subtropical Convergence Zone continue to create an environment productive enough to support the world's largest living mammals during their migratory foraging movements between the Southern Ocean and Indonesia.

Published
2018

50. The Case of John and Juliet: TV Reboots, Gender Swaps, and the Denial of Queer Identity

Author

Jenner Mareike

Subjects
middlebrow tv, gender swap, visibility politics, Social sciences (General), H1-99
Abstract

This article deals with issues of diversity and “visibility politics” in contemporary American middlebrow television. The focus here is specifically how the reboots of Hawaii Five-0 approach these issues. This article uses the gender swap Magnum, P.I., where Higgins (John Hillerman/Perdita Weeks) is rendered female, as an example to explore how feminism and queer visibility are pitted against each other, while being rendered politically mute. While contemporary US middlebrow TV features a lot of racial, gender, and body and ability diversity, many of these issues are approached as visual rather than political. Drawing on different theories on representation and visibility of marginalised groups, this article argues that middlebrow TV reboots aim for a higher degree of inclusion than original series, without fully responding to the political agendas linked to equality and civil rights. Reducing political issues to questions of visibility results in a “flattening out” of goals White maintaining an ideology of “political neutrality.”

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results